Literature DB >> 12638782

Clinical management of low ovarian response to stimulation for IVF: a systematic review.

B C Tarlatzis1, L Zepiridis, G Grimbizis, J Bontis.   

Abstract

Poor response is not a rare occurrence in ovarian stimulation. Although not fully accepted, the most dominant criteria for poor ovarian response are small numbers of follicles developed or oocytes retrieved, and low estradiol (E2) levels after the use of a standard stimulation protocol. There is no ideal predictive test as the poor responder is revealed only during ovulation induction; however, increased levels of day 3 FSH and E2 as well as decreased levels of inhibin B can be used to assess ovarian reserve. Several protocols have been proposed for clinical management of low ovarian response in IVF. Although high doses of gonadotrophins have been used by the vast majority of authors, results have been controversial and prospective randomized studies have shown little or no benefit. The few available relevant studies do not indicate that recombinant FSH improves outcome. Flare-up GnRH agonist protocols (including all dosage varieties) produce better results than standard long luteal protocols. Luteal initiation GnRH agonist 'stop' protocols were shown to improve ovarian response according to prospective studies with historical controls, but this was not confirmed by well-designed prospective, randomized, controlled studies. The few available data obtained with GnRH antagonists have not shown any benefits. Adjuvant therapy with growth hormone (GH) or GH-releasing factors results in no significant improvement. The use of corticosteroids reduces the incidence of poor ovarian response in women undergoing IVF treatment. The limited data obtained with nitric oxide donors are encouraging. Pretreatment with combined oral contraceptives prior to stimulation may help ovarian response. No benefit was observed with standard use of ICSI or assisted hatching of zona pellucida. Finally, natural cycle IVF has produced results which are comparable with those obtained with stimulated cycles in true poor responders. Well-designed, large-scale, randomized, controlled trials are needed to assess the efficacy of these different management strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12638782     DOI: 10.1093/humupd/dmg007

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  53 in total

1.  Effect of estrogen priming through luteal phase and stimulation phase in poor responders in in-vitro fertilization.

Authors:  Eun Mi Chang; Ji Eun Han; Hyung Jae Won; You Shin Kim; Tae Ki Yoon; Woo Sik Lee
Journal:  J Assist Reprod Genet       Date:  2011-12-08       Impact factor: 3.412

2.  Different ovarian response by age in an anti-Müllerian hormone-matched group undergoing in vitro fertilization.

Authors:  Hiroyuki Honnma; Tsuyoshi Baba; Masahiro Sasaki; Yoshiki Hashiba; Hisanori Oguri; Takanori Fukunaga; Toshiaki Endo; Yoshimasa Asada
Journal:  J Assist Reprod Genet       Date:  2011-11-16       Impact factor: 3.412

3.  C-type natriuretic peptide stimulates ovarian follicle development.

Authors:  Yorino Sato; Yuan Cheng; Kazuhiro Kawamura; Seido Takae; Aaron J W Hsueh
Journal:  Mol Endocrinol       Date:  2012-05-17

4.  Circulating nitric oxide in women affected by weight loss amenorrhea during pulsatile gonadotropin-releasing hormone therapy.

Authors:  S Valenti; D Cavallero; L Fazzuoli; F Minuto; M Giusti
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

Review 5.  Is there a recommended maximum starting dose of FSH in IVF?

Authors:  Luk Rombauts
Journal:  J Assist Reprod Genet       Date:  2007-06-17       Impact factor: 3.412

6.  Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial.

Authors:  Marzieh Aghahosseini; Ashraf Aleyassin; Sepideh Khodaverdi; Fatemeh Esfahani; Robabeh Mohammadbeigi; Shohreh Movahedi; Ali Kord Valeshabad; Atossa Mahdavi; Parvin Fallahi; Parisa Shabani; Zahra Rezaeeian; Maryam Khodaverdi
Journal:  J Assist Reprod Genet       Date:  2011-07-01       Impact factor: 3.412

7.  Effects of prolonging administration gonadotropin on unexpectedly poor ovarian responders undergoing in vitro fertilization.

Authors:  Zhaolian Wei; Xianxia Cheng; Huirong Li; Yunxia Cao; Lin Cong; Ping Zhou; Jun Li
Journal:  Reprod Biol Endocrinol       Date:  2010-03-17       Impact factor: 5.211

8.  Discordances between follicle stimulating hormone (FSH) and anti-Müllerian hormone (AMH) in female infertility.

Authors:  Norbert Gleicher; Andrea Weghofer; David H Barad
Journal:  Reprod Biol Endocrinol       Date:  2010-06-17       Impact factor: 5.211

9.  Controlled ovarian stimulation therapy as a potential risk for the development and progression of renal cell carcinomas: A case report and literature review.

Authors:  Sotirios G Doukas; Boris Martinez; Marnie E Rosenthal; Dimitra P Vageli
Journal:  Mol Clin Oncol       Date:  2021-05-23

Review 10.  Approaches to improve the diagnosis and management of infertility.

Authors:  P Devroey; B C J M Fauser; K Diedrich
Journal:  Hum Reprod Update       Date:  2009-04-20       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.